TY - JOUR
T1 - Circulating microRNAs in Alzheimer's disease
T2 - The search for novel biomarkers
AU - Dorval, Véronique
AU - Nelson, Peter T.
AU - Hébert, Sébastien S.
PY - 2013/8/30
Y1 - 2013/8/30
N2 - Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly. While advancements have been made in understanding the genetic and molecular basis of AD, the clinical diagnosis of AD remains difficult, and post-mortem confirmation is often required. Furthermore, the onset of neurodegeneration precedes clinical symptoms by approximately a decade. Consequently, there is a crucial need for an early and accurate diagnosis of AD, which can potentially lead to strategies that can slow down or stop the progression of neurodegeneration and dementia. Recent advances in the non-coding RNA field have shown that microRNAs (miRNAs) can function as powerful biomarkers in human diseases. Studies are emerging suggesting that circulating miRNAs in the cerebrospinal fluid and blood serum have characteristic changes in AD patients. Whether miRNAs can be used in AD diagnosis, alone or in combination with other AD biomarkers (e.g., amyloid and tau), warrants further investigation.
AB - Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly. While advancements have been made in understanding the genetic and molecular basis of AD, the clinical diagnosis of AD remains difficult, and post-mortem confirmation is often required. Furthermore, the onset of neurodegeneration precedes clinical symptoms by approximately a decade. Consequently, there is a crucial need for an early and accurate diagnosis of AD, which can potentially lead to strategies that can slow down or stop the progression of neurodegeneration and dementia. Recent advances in the non-coding RNA field have shown that microRNAs (miRNAs) can function as powerful biomarkers in human diseases. Studies are emerging suggesting that circulating miRNAs in the cerebrospinal fluid and blood serum have characteristic changes in AD patients. Whether miRNAs can be used in AD diagnosis, alone or in combination with other AD biomarkers (e.g., amyloid and tau), warrants further investigation.
KW - Alzheimer's disease
KW - Biomarker
KW - Diagnosis
KW - Mild cognitive impairment
KW - microRNA
UR - http://www.scopus.com/inward/record.url?scp=84885070998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885070998&partnerID=8YFLogxK
U2 - 10.3389/fnmol.2013.00024
DO - 10.3389/fnmol.2013.00024
M3 - Article
AN - SCOPUS:84885070998
SN - 1662-5099
VL - 6
JO - Frontiers in Molecular Neuroscience
JF - Frontiers in Molecular Neuroscience
IS - AUG
M1 - 24
ER -